The antibody recognizes the typical amyloid deposits in brains of patients suffering from the disease. This antibody has been developed against the carboxy terminal extracellular sequence of the mutated BRI protein.
ITM2B
Reactivité: Humain
ELISA
Hôte: Lapin
Polyclonal
Biotin
Indications d'application
Suitable for Immunohistochemistry on frozen sections. Suggested positive control: pathological brain sections. (Not recommended in Western blots). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg /ml
Buffer
PBS, pH 7.2, containing 0.09 % sodium azide as preservative.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Avoid repeated freezing and thawing.
Stock
4 °C/-20 °C
Stockage commentaire
Store the antibody at 2-8 °C (Lyophilized) or reconstituted in small aliquots at -20 °C.
Antigène
ITM2B
(Integral Membrane Protein 2B (ITM2B))
Autre désignation
ITM2B
Sujet
The mutated BRI protein (ITM2B) was identified in patients with familial British dementia. The unusual 277 residue precursor protein releases a 34-residue amyloidogenic peptide by the action of the protease furin, leading to the deposition of a protein fragment that seems to be involved in the pathogenesis of familial British dementia.Synonyms: BRI, BRI2, ITM2B, Integral membrane protein 2B, Transmembrane protein BRI